{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:53:17Z","timestamp":1794135197339,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>SYFOVRE, the brand name of pegcetacoplan and the first FDA-approved treatment for geographic atrophy arising from dry age-related macular degeneration, is currently available only in vial format. Consequently, it is often compounded and transferred into syringes. This study aims to identify the optimal syringe type for both storage and intravitreal injection (IVI) of medium- and high-viscosity formulations such as SYFOVRE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SYFOVRE was prepared in four syringe types and stored under refrigeration in amber bags for up to 110 days. Samples were evaluated for potency, aggregation, protein integrity, binding activity, pH, appearance, sterility, and container closure integrity. Syringe particulate contribution was examined using light obscuration. Injectability of each syringe was assessed through administration of 15 cP and 120 cP viscosity mimics into the vitreous of human cadaver eyes, and injection force was recorded over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pegcetacoplan remained stable across all syringe types for 110 days. The ClearJect (0.5 mL) syringe exceeded particulate safety limits as defined by USP\u2009&lt;789&gt;. Ophthalmic-specific syringes (Zero Residual [0.2 mL] and StaClear [0.25 mL]) required significantly lower injection forces than the BD (1 mL) and ClearJect (0.5 mL) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While all syringes preserved stability of SYFOVRE, injection force increased with higher viscosity. The borosilicate syringe (ClearJect) failed particulate testing, disqualifying it as a viable IVI option. Low-volume ophthalmic-specific syringes (Zero Residual and StaClear) demonstrated superior performance, suggesting they should be used for the safer delivery of intravitreal therapies. Notably, Zero Residual is the only IVI-indicated syringe that eliminates silicone oil\u2013associated risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00832-3","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:23:13Z","timestamp":1773314593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Guiding syringe selection for intravitreal injections: injectability and stability analysis of compounded pegcetacoplan (SYFOVRE) and the broader implications for high-viscosity ophthalmic therapies"],"prefix":"10.1186","volume":"12","author":[{"given":"Tina","family":"Felfeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrem D.","family":"Mandelcorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"xli","DOI":"10.1016\/j.ajo.2017.12.019","volume":"191","author":"DF Martin","year":"2018","unstructured":"Martin DF. Evolution of intravitreal therapy for retinal disease - from CMV to CNV. Am J Ophthalmol. 2018;191:xli\u2013lviii. https:\/\/doi.org\/10.1016\/j.ajo.2017.12.019.","journal-title":"Am J Ophthalmol"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","volume":"7","author":"WJ Anderson","year":"2021","unstructured":"Anderson WJ, Da Cruz NFS, Lima LH, et al. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021;7:37. https:\/\/doi.org\/10.1186\/s40942-021-00307-7.","journal-title":"Int J Retina Vitreous"},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10:13248. https:\/\/doi.org\/10.1038\/s41598-020-70269-7.","journal-title":"Sci Rep"},{"key":"832_CR4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","volume":"28","author":"SJ Bakri","year":"2008","unstructured":"Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina. 2008;28:996\u20131001. https:\/\/doi.org\/10.1097\/IAE.0b013e31816c6868.","journal-title":"Retina"},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamaophthalmol.2017.1815","volume":"135","author":"RN Khurana","year":"2017","unstructured":"Khurana RN, Chang LK, Porco TC. Incidence of presumed silicone oil droplets in the vitreous cavity after intravitreal bevacizumab injection with insulin syringes. JAMA Ophthalmol. 2017;135:800\u20133. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1815.","journal-title":"JAMA Ophthalmol"},{"key":"832_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajoc.2017.07.009","volume":"10","author":"JH Yu","year":"2018","unstructured":"Yu JH, Gallemore E, Kim JK, et al. Silicone oil droplets following intravitreal bevacizumab injections. Am J Ophthalmol Case Rep. 2018;10:142\u20134. https:\/\/doi.org\/10.1016\/j.ajoc.2017.07.009.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/ICB.0000000000000570","volume":"0","author":"RL Avery","year":"2019","unstructured":"Avery RL, Castellarin AA, Dhoot DS, et al. Large silicone droplets after intravitreal bevacizmab (Avastin). Retinal Cases Brief Rep. 2019;0:130\u20134. https:\/\/doi.org\/10.1097\/ICB.0000000000000570.","journal-title":"Retinal Cases Brief Rep"},{"key":"832_CR8","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1002\/jps.21719","volume":"98","author":"R Thirumangalathu","year":"2009","unstructured":"Thirumangalathu R, Krishnan S, Ricci MS, et al. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci. 2009;98:3167\u201381. https:\/\/doi.org\/10.1002\/jps.21719.","journal-title":"J Pharm Sci"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.xphs.2016.02.019","volume":"105","author":"CF Chisholm","year":"2016","unstructured":"Chisholm CF, Baker AE, Soucie KR, et al. Silicone oil microdroplets can induce antibody responses against recombinant murine growth hormone in mice. J Pharm Sci. 2016;105:1623\u201332. https:\/\/doi.org\/10.1016\/j.xphs.2016.02.019.","journal-title":"J Pharm Sci"},{"key":"832_CR10","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.xphs.2019.02.002","volume":"108","author":"E Krayukhina","year":"2019","unstructured":"Krayukhina E, Yokoyama M, Hayashihara KK, et al. An assessment of the ability of submicron- and micron-size silicone oil droplets in dropped prefillable syringes to invoke early- and late-stage immune responses. J Pharm Sci. 2019;108:2278\u201387. https:\/\/doi.org\/10.1016\/j.xphs.2019.02.002.","journal-title":"J Pharm Sci"},{"key":"832_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40942-022-00387-z","volume":"8","author":"NFS da Cruz","year":"2022","unstructured":"da Cruz NFS, Polizelli MU, Muralha FP, et al. Ocular inflammation after agitation of siliconized and silicone oil-free syringes: a randomized, double-blind, controlled clinical trial. Int J Retina Vitreous. 2022;8:41. https:\/\/doi.org\/10.1186\/s40942-022-00387-z.","journal-title":"Int J Retina Vitreous"},{"key":"832_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.oret.2024.09.008","volume":"9","author":"MLD dos Santos","year":"2025","unstructured":"dos Santos MLD, Agra LLM, Cardoso VS, et al. Intravitreal silicone oil with silicone-free versus a siliconized syringe. Ophthalmol Retina. 2025;9:89\u201391. https:\/\/doi.org\/10.1016\/j.oret.2024.09.008.","journal-title":"Ophthalmol Retina"},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.clinthera.2021.08.011","volume":"43","author":"NM Schultz","year":"2021","unstructured":"Schultz NM, Bhardwaj S, Barclay C, et al. Global burden of Dry Age-Related Macular Degeneration: A targeted literature review. Clin Ther. 2021;43:1792\u2013818. https:\/\/doi.org\/10.1016\/j.clinthera.2021.08.011.","journal-title":"Clin Ther"},{"key":"832_CR14","unstructured":"Bandello F. AMD: age-related macular degeneration. 1st Edition. Porto, Portugal: Th\u00e9a Portugal, SA; 2010."},{"key":"832_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2131\/fts.10.157","volume":"10","author":"M Sakata","year":"2023","unstructured":"Sakata M, Araki T, Tomohiro M. Evaluation of maximal dosing volume for intravitreal injections in cynomolgus monkeys. Fundamental Toxicol Sci. 2023;10:157\u201367. https:\/\/doi.org\/10.2131\/fts.10.157.","journal-title":"Fundamental Toxicol Sci"},{"key":"832_CR16","doi-asserted-by":"publisher","first-page":"e10632","DOI":"10.1002\/btm2.10632","volume":"9","author":"C Huang","year":"2024","unstructured":"Huang C, Wang Y, Huang J, et al. A bioengineered anti-VEGF protein with high affinity and high concentration for intravitreal treatment of wet age\u2010related macular degeneration. Bioeng Translational Med. 2024;9:e10632. https:\/\/doi.org\/10.1002\/btm2.10632.","journal-title":"Bioeng Translational Med"},{"key":"832_CR17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamaophthalmol.2023.3495","volume":"141","author":"J Bijon","year":"2023","unstructured":"Bijon J, Mundae R, Fisher Y, Freund KB. Multiple small floaters associated with silicone oil droplets following intravitreal pegcetacoplan injection. JAMA Ophthalmol. 2023;141:907.","journal-title":"JAMA Ophthalmol"},{"key":"832_CR18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaophthalmol.2023.4326","volume":"141","author":"A Dessouki","year":"2023","unstructured":"Dessouki A, He L, Park K, et al. Presumed silicone oil droplets after intravitreal pegcetacoplan injections. JAMA Ophthalmol. 2023;141:1062.","journal-title":"JAMA Ophthalmol"},{"key":"832_CR19","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.preteyeres.2020.100862","volume":"80","author":"GB Melo","year":"2021","unstructured":"Melo GB, Cruz NFSD, Emerson GG, et al. Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections. Prog Retin Eye Res. 2021;80:100862.","journal-title":"Prog Retin Eye Res"},{"key":"832_CR20","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1097\/IAE.0000000000004512","volume":"45","author":"L Wei","year":"2025","unstructured":"Wei L, Lee E, Fan X, Thompson JT. Silicon oil microdroplets from syringes with intravitreal anti-vascular endothelial growth factor and complement inhibitor injections. RETINA. 2025;45:1744\u201350.","journal-title":"RETINA"},{"key":"832_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","volume":"135","author":"BD Eadie","year":"2017","unstructured":"Eadie BD, Etminan M, Carleton BC, et al. Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol. 2017;135:363\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0059.","journal-title":"JAMA Ophthalmol"},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00417-019-04362-7","volume":"257","author":"QN Cui","year":"2019","unstructured":"Cui QN, Gray IN, Yu Y, VanderBeek BL. Repeated intravitreal injections of antivascular endothelial growth factors and risk of intraocular pressure medication use. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2019;257:1931\u20139. https:\/\/doi.org\/10.1007\/s00417-019-04362-7.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"key":"832_CR23","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/s41433-020-01211-4","volume":"35","author":"K Gallagher","year":"2021","unstructured":"Gallagher K, Raghuram AR, Williams GS, Davies N. Pre-filled aflibercept syringes\u2014variability in expressed fluid volumes and a case series of transient central retinal artery occlusions. Eye. 2021;35:2899\u2013900. https:\/\/doi.org\/10.1038\/s41433-020-01211-4.","journal-title":"Eye"},{"key":"832_CR24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1007\/s11095-011-0621-4","volume":"29","author":"A Seidl","year":"2012","unstructured":"Seidl A, Hainzl O, Richter M, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454\u201367. https:\/\/doi.org\/10.1007\/s11095-011-0621-4.","journal-title":"Pharm Res"},{"key":"832_CR25","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1002\/jps.23224","volume":"101","author":"OS Kumru","year":"2012","unstructured":"Kumru OS, Liu J, Ji JA, et al. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci. 2012;101:3636\u201350. https:\/\/doi.org\/10.1002\/jps.23224.","journal-title":"J Pharm Sci"},{"key":"832_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jps.22739","volume":"101","author":"A Sreedhara","year":"2012","unstructured":"Sreedhara A, Glover ZK, Piros N, et al. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci. 2012;101:21\u201330. https:\/\/doi.org\/10.1002\/jps.22739.","journal-title":"J Pharm Sci"},{"key":"832_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.iae.0000225354.92444.7a","volume":"26","author":"SJ Bakri","year":"2006","unstructured":"Bakri SJ, Snyder MR, Pulido JS, et al. Six-month stability of bevacizumab (Avastub) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina. 2006;26:519\u201322. https:\/\/doi.org\/10.1097\/01.iae.0000225354.92444.7a.","journal-title":"Retina"},{"key":"832_CR28","doi-asserted-by":"publisher","first-page":"18021","DOI":"10.1038\/s41598-019-54226-7","volume":"9","author":"HE Lode","year":"2019","unstructured":"Lode HE, Gj\u00f8lberg TT, Foss S, et al. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Sci Rep. 2019;9:18021. https:\/\/doi.org\/10.1038\/s41598-019-54226-7.","journal-title":"Sci Rep"},{"key":"832_CR29","doi-asserted-by":"publisher","first-page":"882013","DOI":"10.3389\/fopht.2022.882013","volume":"2","author":"TT Gj\u00f8lberg","year":"2022","unstructured":"Gj\u00f8lberg TT, Lode HE, Melo GB, et al. A silicon oil-free syringe tailored for intravitreal injection of biologics. Front Ophthalmol. 2022;2:882013. https:\/\/doi.org\/10.3389\/fopht.2022.882013.","journal-title":"Front Ophthalmol"},{"key":"832_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40942-023-00507-3","volume":"9","author":"\u00d8K J\u00f8rstad","year":"2023","unstructured":"J\u00f8rstad \u00d8K, Foss S, Gj\u00f8lberg TT, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties. Int J Retina Vitreous. 2023;9:65. https:\/\/doi.org\/10.1186\/s40942-023-00507-3.","journal-title":"Int J Retina Vitreous"},{"key":"832_CR31","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1021\/bc049843w","volume":"15","author":"CJ Fee","year":"2004","unstructured":"Fee CJ, Van Alstine JM. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug Chem. 2004;15:1304\u201313.","journal-title":"Bioconjug Chem"},{"key":"832_CR32","unstructured":"Allen LV, Bassani GS, Elder EJ, Parr AF. Strength and stability testing for compounded preparations. Published online May 2015."},{"key":"832_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/bit.22014","volume":"101","author":"JA Rodr\u00edguez-Mart\u00ednez","year":"2008","unstructured":"Rodr\u00edguez-Mart\u00ednez JA, Sol\u00e1 RJ, Castillo B, et al. Stabilization of \u03b1\u2010chymotrypsin upon PEGylation correlates with reduced structural dynamics. Biotechnol Bioeng. 2008;101:1142\u20139. https:\/\/doi.org\/10.1002\/bit.22014.","journal-title":"Biotechnol Bioeng"},{"key":"832_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12257-019-0363-4","volume":"24","author":"A Purkayastha","year":"2019","unstructured":"Purkayastha A, Kang TJ. Stabilization of proteins by covalent cyclization. Biotechnol Bioprocess Eng. 2019;24:702\u201312. https:\/\/doi.org\/10.1007\/s12257-019-0363-4.","journal-title":"Biotechnol Bioprocess Eng"},{"key":"832_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40942-018-0143-x","volume":"4","author":"J de Lima Farah","year":"2018","unstructured":"de Lima Farah J, Sano R, Maug\u00e9ri IML, et al. Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding. Int J Retina Vitreous. 2018;4:39. https:\/\/doi.org\/10.1186\/s40942-018-0143-x.","journal-title":"Int J Retina Vitreous"},{"key":"832_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jps.24184","volume":"104","author":"E Krayukhina","year":"2015","unstructured":"Krayukhina E, Tsumoto K, Uchiyama S, Fukui K. Effects of syringe material and silicon oil lubrication on the stability of pharmaceutical proteins. J Pharm Sci. 2015;104:527\u201335. https:\/\/doi.org\/10.1002\/jps.24184.","journal-title":"J Pharm Sci"},{"key":"832_CR37","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/jps.20321","volume":"94","author":"LS Jones","year":"2005","unstructured":"Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci. 2005;94:918\u201327. https:\/\/doi.org\/10.1002\/jps.20321.","journal-title":"J Pharm Sci"},{"key":"832_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3389\/fbioe.2018.00199","volume":"6","author":"NK Tram","year":"2018","unstructured":"Tram NK, Swindle-Reilly KE. Rheological properties and age-related changes of the human vitreous humor. Front Bioeng Biotechnol. 2018;6:199.","journal-title":"Front Bioeng Biotechnol"},{"key":"832_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00397-017-0997-0","volume":"56","author":"AF Silva","year":"2017","unstructured":"Silva AF, Alves MA, Oliveira MSN. Rheological behaviour of vitreous humour. Rheol Acta. 2017;56:377\u201386.","journal-title":"Rheol Acta"},{"key":"832_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajo.2022.03.023","volume":"241","author":"WJ Foster","year":"2022","unstructured":"Foster WJ, Berg BW, Luminais SN, et al. Computational modeling of ophthalmic procedures. Am J Ophthalmol. 2022;241:87\u2013107.","journal-title":"Am J Ophthalmol"},{"key":"832_CR41","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.oret.2023.06.003","volume":"7","author":"LLM Agra","year":"2023","unstructured":"Agra LLM, Sverstad A, Chagas TA, et al. Accuracy, precision, and residual volume of commonly used syringes for intravitreal injections and the impact on intraocular pressure. Ophthalmol Retina. 2023;7:892\u2013900. https:\/\/doi.org\/10.1016\/j.oret.2023.06.003.","journal-title":"Ophthalmol Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00832-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:57:08Z","timestamp":1781639828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00832-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00832-3","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the University Health Network Ethics Review Board (23-6021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, consent to participate, and consent to publish"}},{"value":"Pegcetacoplan (SYFOVRE), the first FDA-approved therapy for dry AMD supplied only in vial format, requires careful syringe selection due to its high viscosity. In this study, stability was preserved across syringe types, but injectability and particulate burden varied. Ophthalmic-specific syringes, especially Zero Residual and StaClear, outperformed conventional syringes, supporting safer, more efficient intravitreal delivery.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Brief summary statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}